By Sriparna Roy

(Reuters) -Crystalys Therapeutics said on Tuesday it has emerged from stealth mode with a funding round of $205 million to help finance global late-stage trials of its lead drug as a treatment for gout.

The Series A financing round was co-led by Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, SR One and Catalys Pacific, and had participation from other investors.

The company, which had a pre-money valuation of $75 million, had closed an initial investment in June, and had been working with three to four additional investors for a second capital raise, CEO James Mackay told Reuters.

Crystalys is accelerating two late-stage trials of dotinurad, a once-daily oral drug being evaluated in the U.S. and Europe as a second-line treatment for gout i

See Full Page